An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
NATICK, Mass. - Mercy BioAnalytics announced that Dawn Mattoon, PhD, has taken over as Chief Executive Officer, transitioning from her previous role as Chief Operating Officer. Paul Blavin has moved to the position of Vice Chairman of the Board. Dr. Mattoon, who has been with the company for seven months, praised the team's progress in advancing their cancer detection technology. Her experience includes leadership roles in strategic initiatives at companies like Quanterix and Thermo Fisher Scientific. The company focuses on the early detection of cancers, particularly ovarian and lung cancers, through its Mercy Halo liquid biopsy platform.
Positive
Dawn Mattoon appointed CEO, bringing extensive industry experience.
Continued focus on early cancer detection, particularly for lethal cancers like ovarian and lung cancers.
Mercy Halo technology aims to improve early cancer detection and treatment outcomes.
Negative
Transition in leadership may present continuity challenges.
NATICK, Mass.--(BUSINESS WIRE)--
Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that Dawn Mattoon, PhD, has assumed the role of Chief Executive Officer and a member of the company’s Board of Directors, transitioning from her prior role as Chief Operating Officer as part of the company’s succession planning. Paul Blavin has transitioned from his CEO role to Vice Chairman of the Board.
“We founded Mercy to solve the inherent challenges in others’ use of scarce circulating tumor DNA (ctDNA), which has not been able to reliably detect cancer at its earliest stages,” said Blavin. “At the same time, we created a unique culture that emphasizes humility, collaboration and a sense of urgency to create better tools with a transformational approach. It has been an honor to lead this exceptional company and I am excited to hand the reigns to a remarkable leader with the experience and passion to lead Mercy to clinical and commercial impact. Dawn joins the ranks of a very small group of women leading game-changing diagnostics companies. I look forward to continuing to contribute to Mercy’s mission in my role as Vice Chairman.”
“I am grateful for the opportunity to lead this pioneering organization in realizing our mission to save lives and relieve suffering through the early detection of cancer. In my seven months with the company, I have been consistently impressed with the progress that has been made by our committed team, Board and advisors in advancing our innovative Mercy Halo test portfolio through the conduct of exceptionally rigorous early science and data-based decision-making,” said Dr. Mattoon. “I have been blessed in my career to be part of building several thriving businesses around novel products with real impact; Mercy stands out among peer companies and I am honored to lead the team in realizing the promise of reliable early cancer detection.”
Dr. Mattoon has served as COO of Mercy BioAnalytics since July 2022. In her nearly 20-year career, she has built a track record of delivering top and bottom-line growth as a leader in research and development, strategy, commercialization, and general management for a broad range of innovative proteomic and genomic companies such as Quanterix Corporation (Nasdaq: QTRX), Invitrogen, Life Technologies, Thermo Fisher Scientific Inc. (NYSE: TMO), and Cell Signaling Technologies. She holds a PhD in molecular genetics from Yale University, where she also completed her postdoctoral fellowship. Dr. Mattoon joins the ranks of a very small group of women leading game-changing diagnostics companies.
Mr. Blavin is co-founder of Mercy BioAnalytics and served as its CEO from March 2020 through February 2023. Prior to Mercy, his 30-year career in finance encompassed tenures as President of insurance holding company First Mercury Financial Corporation; co-founder of PWB Value Partners, LP, an investment partnership managing $2 billion in assets; and investment banker with Citibank and Donaldson, Lufkin & Jenrette. He is an active philanthropist having established a number of successful programs benefitting underserved populations. He earned an MBA from Harvard Business School and holds a bachelor’s degree in accounting from the University of Michigan.
ABOUT MERCY BIOANALYTICS
Mercy BioAnalytics, Inc.is on a mission to relieve suffering and save lives through the early detection of cancer.Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant blood based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo™ platform is designed to detect stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy’s initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast, prostate, and colorectal cancers combined. For additional information, please visit https://www.mercybio.com.
Who is the new CEO of Mercy BioAnalytics and what is her background?
The new CEO of Mercy BioAnalytics is Dawn Mattoon, PhD. She has nearly 20 years of experience in research and development, strategy, and commercialization, having previously worked at Quanterix and Thermo Fisher Scientific.
What position did Paul Blavin assume after stepping down as CEO?
After stepping down as CEO, Paul Blavin became the Vice Chairman of the Board.
What are the primary goals of Mercy BioAnalytics under the new leadership?
Under Dawn Mattoon’s leadership, Mercy BioAnalytics aims to enhance early detection of cancer using the Mercy Halo liquid biopsy platform.
When did Dawn Mattoon start her role as CEO at Mercy BioAnalytics?
Dawn Mattoon assumed the role of CEO in February 2023.
What technology does Mercy BioAnalytics focus on for cancer detection?
Mercy BioAnalytics focuses on the Mercy Halo liquid biopsy platform, designed to detect early-stage cancers.
